Sequella Home Page

Quick Facts

An estimated 60,000 cases of MDR-TB a year are not responding to standard TB drug treatment

Management

Carol A. Nacy, Ph.D.

Co-Founder, Chief Executive Officer, Chairman of the Board of Directors
Dr. Nacy co-founded our company in 1997 and has served as our CEO and Chairman of the Board since 1999. Prior to devoting herself full-time to Sequella, Dr. Nacy served during 1997 and 1998 as part-time Chief Scientific Officer (CSO) for Anergen, Inc., a California company focused on autoimmune diseases, where she reorganized the scientific staff and positioned the company for acquisition by Corixa Corporation in December 1998. From 1993 through 1997, Dr. Nacy was Executive Vice President and CSO at EntreMed, Inc., serving that company through its successful public offering in June 1996. Previously, Dr. Nacy was Career Scientist (GS-15) and Science Manager at the Walter Reed Army Institute of Research, Washington, DC. In addition to her service to Sequella, Dr. Nacy currently serves as a member of the board of directors of several companies and non-profit agencies. She maintains strong ties to the scientific research community, serving as President of the 43,000 member American Society for Microbiology in 1996 and on the Board of the National Academy of Science, National Research Council from 1996-2003.

Leo Einck, Ph.D.

Co-Founder, Director, and Chief Scientific Officer
Dr. Einck, a co-founder of our company, joined Sequella as President in 1998. He has been involved in the pharmaceutical industry since 1985, and has started and managed several biotechnology companies since his shift to product development. He was the first employee of and later became the Chief Operating Officer of HEM (now Hemispherix), a public company specializing in double-stranded RNA therapeutics for cancer. He managed all aspects of HEM's business, from manufacturing, clinical trials, regulatory affairs, to daily operations. He joined EntreMed, Inc. in 1993 as Director of Sponsored Research, became Vice-President for Extramural Programs in 1996, and then the Vice President for Research Operations. Prior to his business experience, Dr. Einck was a molecular biologist at the National Cancer Institute of the NIH.

Lisa Beth Ferstenberg, M.D.

Medical Director
Dr. Ferstenberg has spent over 30 years in biopharmaceutical development and has a depth of experience in clinical trials purposed for regulatory submissions and drug approvals. Her areas of specialization include oncology, immunology, vaccines, and infectious diseases of global importance such as TB, HIV, malaria and others. She has a particular focus on pharmacovigilance for developing and marketed drugs and has been trained in MedDRA coding of terms. Dr. Ferstenberg has held senior executive positions in several early stage pharmaceutical and biotechnology companies, and is a serial entrepreneur with a history of successful fund-raising efforts and exits. She is the Lead Instructor for the Innovate Program, which trains life scientists in business fundamentals and entrepreneurship, and is an advisor to Montgomery County Economic Development on issues of importance to early stage companies in the Maryland Biotech Corridor. 

Alan S. Klein

Executive Vice President, Corporate Development  
Mr. Klein joined Sequella in 2003. In the last 18 years, he has had a number of leadership positions in business management, business development, and corporate development in the pharmaceutical/biotech industry. Prior to joining Sequella, Mr. Klein served as Vice President at GeneLogic, Inc. (NASDAQ:GLGC); Senior Director, Business Development at CuraGen Corporation (NASDAQ:CRGN); held a number of Senior Director level positions at Quintiles Transnational in the Infectious Diseases, Respiratory, and Immunology Therapeutic Areas; and Director, Business Development for PharmaKinetics Laboratories (OTC:PKLB).

Marina Protopopova, Ph.D.

Vice President, Drug Discovery
Dr. Protopopova joined Sequella in 1999 as a Senior Scientist responsible for identifying new TB drugs. She was promoted to Director of Chemistry in 2001, and was named Vice President of Drug Discovery in 2006. From 2000 to 2006, she played a key role in advancing the Sequella drug candidate SQ109 from discovery in 2000 to IND-directed preclinical studies and into clinical development in 2006. She now oversees drug discovery and pre-clinical research programs, including toxicology, chemistry, pharmacology, and biology. Her scientific career spans over 20 years, including work experience in both the United States and Russia. She worked at the National Institutes of Health (NIH) under a Sequella CRADA, where she initiated a combinatorial chemistry program for discovery of new antibiotics that was moved to Sequella in 2000. Prior to her employment at Sequella, she worked with Regis Technologies in IL to develop new chiral catalysts and proprietary combinatorial chemistry technology for chromatographic applications. While in Russia, Dr. Protopopova was involved in a National Program for the development of novel technologies for production of pyrethroid insecticides in the (former) USSR. Dr. Protopopova has authored several issued patents, and over 40 publications in leading chemistry and scientific journals. She holds a Ph.D. from Zelinskii Institute of Organic Chemistry of the Russian Academy of Sciences and earned a M.S. from Moscow State University.